Replies to post #228020 on Biotech Values

[dewophile]

This would be the third different company BMY markets a drug with in the blood thinner arena if successful - pretty unusual

[DewDiligence]

BMY/JNJ—Slides #21-24 from today’s webcast contain info on BMS-986177 program (FXIa inhibitor):

https://s21.q4cdn.com/104148044/files/doc_presentations/2020/BMY-Investor-Series-Day3.pdf